免疫抑制剂对肾移植术后新发糖尿病的影响  

Impact of immunosuppressive agents on new-onset diabetes mellitus after kidney transplantation

作　　者：宫雅南[1] 陈兴[1] 李万根[2] 方佳丽[3] 廖德怀[3] 陈正[3] 潘光辉[3] 陈丽纯[4] 

机构地区：[1]广州医学院第二附属医院老年病科,510260 [2]广州医学院第二附属医院内分泌科,510260 [3]广州医学院第二附属医院肾移植科,510260 [4]广州医学院第二附属医院病案科,510260

出　　处：《中华生物医学工程杂志》2009年第4期289-292,共4页Chinese Journal of Biomedical Engineering

摘　　要：目的探讨免疫抑制剂对肾移植术后新发糖尿病的影响。方法对本院2004至2008年期间实施的同种异体肾移植患者资料进行回顾性分析，研究肾移植术后糖尿病发病情况，并按免疫抑制剂的不同分为环孢素A组和他克莫司两组，探讨不同免疫抑制剂对新发糖尿病的影响。结果人选532例，新发糖尿病发生率6．0％（32／532）。两组患者的年龄、性别、体质量、术前空腹血糖差异无统计学意义（均为P〉0．05）。他克莫司组糖尿病发病率[8．5％（20／236）]明显高于环孢素A组[4．1％（12／296）]，P〈0．05。结论他克莫司可能与新发糖尿病有关。Objective To investigate the influence of immunosuppressive regiment on incidence of new-onset diabetes mellitus （NODM） after kidney transplantation. Methods Clinical data of recipients who underwent kidney transplantation between 2004 and 2008 in our hospital were analyzed retrospectively. They were divided into cyclosporine A group and tacrolimus group according to different immunosuppressive therapy. The incidence of new-onset diabetes mellitus after transplantation was analyzed, and its risk factors were determined by contrast study. Results The incidence of NODM was 6.0% in 532 kidney transplant recipients enrolled. There were no significant differences in age, gender, weight and fasting blood glucose between the two groups （all P〉0.05 ）. NODM incidence in tacrolinms group was significantly higher than that in cyclosporine A group [ 8.5% （20/236） vs 4.1% （12/296）, P〈0.05 ]. Conclusion Tacrolimus therapy may be related to new-onset diabetes mellitus after kidney transplantation.

关 键 词：肾移植 糖尿病 发病率 他克莫司 环孢素A 

分 类 号：R699.2[医药卫生—泌尿科学]